Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.
Clinical role
Notification-only triage and worklist prioritization in parallel with standard of care; cases remain in the standard reading queue.
Images and patients
CT/CTA · Head/Brain
Key limitation
Keep in mind: Not a diagnostic device; inadequate field of view is excluded; the packet supports head CTA/mCTA inputs and full-image clinician review, not diagnosis from the preview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/Brain Input: Filtered DICOM head CTA or mCTA images; adults or transitional adults aged 18 and older; clinical-testing slice thickness 0.5-1.25 mm.
Who uses it?Intended users: Hospital networks and appropriately trained medical specialists.
What does the software produce?Output: A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only, identifying a suspected VO finding; the clinician reviews the original images in PACS.
What is its most important limitation?Key limitation: Not a diagnostic device; inadequate field of view is excluded; the packet supports head CTA/mCTA inputs and full-image clinician review, not diagnosis from the preview.
Clinical takeaway. Clinical role: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.
Evidence takeaway. Evidence from the reviewed source record: FDA retrospective, blinded, multicenter mCTA VO performance study using ground truth from 2+1 U.S. board-certified radiologist reviewers. Primary endpoint: sensitivity 81.4% (95% CI 71.6-89.0) and specificity 85.5% (95% CI 78.0-91.2). Secondary endpoints: NPV 97.6%, PPV 38.4%, PLR 5.6, NLR 0.22, and time-to-notification 1.09 minutes versus 2.23 minutes for the predicate. The FDA packet does not state the study sample size or site count.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.
A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only, identifying a suspected VO finding; the clinician reviews the original images in PACS.
Not a diagnostic device; inadequate field of view is excluded; the packet supports head CTA/mCTA inputs and full-image clinician review, not diagnosis from the preview.
FDA retrospective, blinded, multicenter mCTA VO performance study using ground truth from 2+1 U.S. board-certified radiologist reviewers. Primary endpoint: sensitivity 81.4% (95% CI 71.6-89.0) and specificity 85.5% (95% CI 78.0-91.2). Secondary endpoints: NPV 97.6%, PPV 38.4%, PLR 5.6, NLR 0.22, and time-to-notification 1.09 minutes versus 2.23 minutes for the predicate. The FDA packet does not state the study sample size or site count.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA retrospective, blinded, multicenter mCTA VO performance study using ground truth from 2+1 U.S. board-certified radiologist reviewers. Primary endpoint: sensitivity 81.4% (95% CI 71.6-89.0) and specificity 85.5% (95% CI 78.0-91.2). Secondary endpoints: NPV 97.6%, PPV 38.4%, PLR 5.6, NLR 0.22, and time-to-notification 1.09 minutes versus 2.23 minutes for the predicate. The FDA packet does not state the study sample size or site count.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
BriefCase-Vessel Occlusion LVO & MeVO Triage regulatory performance study summary
DesignRegulatory performance study summarized by ACR AI Central
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K261317
IndependenceIndependence not established
K261317
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K261317. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Filtered DICOM head CTA or mCTA images; adults or transitional adults aged 18 and older; clinical-testing slice thickness 0.5-1.25 mm.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Linux-based cloud server receives filtered DICOM through an image communication/routing module and sends analysis to a desktop feed and non-diagnostic image viewer for PACS follow-up; exact current interfaces and versions are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only, identifying a suspected VO finding; the clinician reviews the original images in PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only, identifying a suspected VO finding; the clinician reviews the original images in PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Linux-based cloud server receives filtered DICOM through an image communication/routing module and sends analysis to a desktop feed and non-diagnostic image viewer for PACS follow-up; exact current interfaces and versions are not established.
Aidoc's current public Security & Privacy page says its security work is led by a CISO and security team, that it has adopted the NIST Cybersecurity Framework, and that its platform runs on AWS and Azure using EDR, encryption, SIEM and CSPM tooling. The page's list of standards and certifications did not load as readable text, so no certification is stated here.
Vendor-wide
Checked 2026-10-25
Vendor-wide marketing statement, not an independent attestation. It does not establish certificate scope or expiry, the controls of this exact release, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Aidoc's security page states that its platform runs on AWS and Azure and that customer data protection is achieved with the use of EDR, encryption, SIEM, CSPM and other technologies.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Aidoc's platform generally and does not scope these capabilities to any specific product release; exact-release scope is not established. The page lists technology categories in use; it states no uptime, alerting or response-time SLAs.
ACR AI Central provides an exact-submission model card for BriefCase-Triage; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor product page, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K261317 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.
Authorized purpose: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.